All In MedTech

FDA Clearance Tracker · P180050

BAROSTIM NEO® System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Aug 16, 2019 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Aug 16, 2019

Approved

Time to decision

239 days

Received Dec 20, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P180050
Device name
BAROSTIM NEO® System
Applicant
Cvrx, Inc.
Applicant location
Minneapolis, MN
Received
Dec 20, 2018
Decided
Aug 16, 2019
Decision
Approved
Supplements
15 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 870.3850

Every decision under product code DSR

FDA's approval statement

As written in FDA's record.

Approval for The BAROSTIM NEO System. The device is indicated for the improvement of symptoms of heart failure. quality of life, six-minute hall walk and functional status, for patients who remain symptomatic despite treatment with guideline-directed medical therapy, are NYHA Class III or Class II (who had a recent history of Class III), have a left ventricular ejection fraction <= 35%, a NT-proBNP < 1600 pg/ml and excluding patients indicated for Cardiac Resynchronization Therapy (CRT) according to AHA/ACC/ESC guidelines.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code DSR (Stimulator, carotid sinus nerve).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Cvrx, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.